Table 2.
Primary and secondary outcomes.
| Hydroxychloro-quine |
Ivermectin |
Povidone-iodine |
Zinc & vitamin C |
Vitamin C | |||||
|---|---|---|---|---|---|---|---|---|---|
| N = 432 | P-value | N = 617 | P-value | N = 735 | P-value | N = 634 | P-value | N = 619 | |
| Primary outcome | |||||||||
| Laboratory-confirmed SARS-CoV-2 infection | 212 (49.1%) | 0.011* | 398 (64.5%) | 0.50 | 338 (46.0%) | 0.011* | 300 (47.3%) | 0.033 | 433 (70.0%) |
| Seropositive | 179 | 0.058 | 308 | 0.56 | 288 | 0.073 | 250 | 0.12 | 348 |
| RNA positive | 32 | 0.10 | 90 | 0.97 | 50 | 0.054 | 50 | 0.14 | 85 |
| Secondary outcomes | |||||||||
| Acute respiratory symptoms | 31 (7.2%) | 0.14 | 35 (5.7%) | 0.012* | 43 (5.9%) | 0.054 | 34 (5.4%) | 0.029 | 69 (11.1%) |
| Symptomatic COVID-19 | 29/212 (13.7%) | 0.80 | 32/398 (8.0%) | 0.0034* | 42/338 (12.4%) | 0.41 | 33/300 (11.0%) | 0.17 | 64/433 (15.0%) |
| Pneumonia requiring hospitalization | 0 (0%) | – | 0 (0%) | – | 0 (0%) | – | 0 (0%) | – | 0 (0%) |
| Deaths | 0 (0%) | – | 0 (0%) | – | 0 (0%) | – | 0 (0%) | – | 0 (0%) |
P-values are for comparison versus vitamin C arm. For primary outcomes and acute respiratory symptoms, p-values adjust for clustering through random effects logistic regression. Respiratory symptoms are defined by any of the following symptoms: fever, cough, shortness of breath, sore throat, runny nose, or change in smell/taste. P-values significant at a Bonferroni-corrected level of 0.0125 are starred. Quantities are number (%) unless otherwise specified.